• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.

作者信息

Bettelli Stefania, Marcheselli Raffaella, Pozzi Samantha, Marcheselli Luigi, Papotti Robel, Forti Elisa, Cox M Christina Christina, Di Napoli Arianna, Tadmor Tamar, Mansueto Giovanna R, Musto Pellegrino, Flenghi Leonardo, Quintini Martina, Galimberti Sara, Lalinga Vittoria, Donati Valentina, Maiorana Antonino, Polliack Aaron, Sacchi Stefano

机构信息

SSD Patologia Molecolare e Medicina Predittiva, AOU Modena, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Italy.

Fondazione Italiana Linfomi - Onlus, Modena, Italy.

出版信息

Leuk Res. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27.

DOI:10.1016/j.leukres.2021.106552
PMID:33689920
Abstract
摘要

相似文献

1
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.细胞起源（COO）、BCL2/MYC状态和国际预后指数（IPI）在真实临床环境中定义了一组预后不良的弥漫性大B细胞淋巴瘤（DLBCL）患者。
Leuk Res. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27.
2
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.MYC/BCL2 蛋白共表达有助于激活 B 细胞型弥漫性大 B 细胞淋巴瘤的生存预后不良，并表现出高危基因表达特征：来自国际弥漫性大 B 细胞淋巴瘤利妥昔单抗-CHOP 联合方案的报告。
Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28.
3
Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.在德国高级非霍奇金淋巴瘤研究组的前瞻性临床试验中，针对弥漫性大 B 细胞淋巴瘤进行治疗，探讨了细胞起源分类和 MYC/BCL2 双表达状态的临床影响。
J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.
4
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤时 MYC 和 BCL2 的共表达。
J Clin Oncol. 2012 Oct 1;30(28):3452-9. doi: 10.1200/JCO.2011.41.0985. Epub 2012 Jul 30.
5
The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.弥漫性大 B 细胞淋巴瘤中 MYC 改变的谱。
Acta Haematol. 2020;143(6):520-528. doi: 10.1159/000505892. Epub 2020 Feb 19.
6
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.免疫组化双打击评分是利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者预后的强有力预测指标。
J Clin Oncol. 2012 Oct 1;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342. Epub 2012 Jun 4.
7
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.MYC和BCL6同时重排及表达对初发弥漫性大B细胞淋巴瘤的预后影响
Oncotarget. 2016 Jan 19;7(3):2401-16. doi: 10.18632/oncotarget.6262.
8
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.COO 和 MYC/BCL2 状态不能预测 I/II 期 DLBCL 患者的预后：一项回顾性多中心研究。
Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251.
9
MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.MYC 和 BCL2 蛋白表达可预测接受利妥昔单抗治疗的弥漫性大 B 细胞淋巴瘤患者的生存情况。
Br J Haematol. 2014 May;165(3):382-91. doi: 10.1111/bjh.12763. Epub 2014 Feb 8.
10
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.通过数字基因表达确定福尔马林固定石蜡包埋组织活检中弥漫性大B细胞淋巴瘤细胞起源的预后意义
J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.

引用本文的文献

1
Efficacy and safety of the R2-MTX regimen in primary central nervous system lymphoma (PCNSL): a single-center retrospective analysis.R2-MTX方案治疗原发性中枢神经系统淋巴瘤（PCNSL）的疗效与安全性：一项单中心回顾性分析
J Cancer Res Clin Oncol. 2025 May 22;151(5):173. doi: 10.1007/s00432-025-06205-x.
2
A new digital droplet PCR method for looking at epigenetics in diffuse large B-cell lymphomas: The role of BMI1, EZH2, and USP22 genes.一种用于研究弥漫性大B细胞淋巴瘤表观遗传学的新型数字液滴PCR方法：BMI1、EZH2和USP22基因的作用
Int J Lab Hematol. 2025 Feb;47(1):101-109. doi: 10.1111/ijlh.14363. Epub 2024 Sep 10.
3
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
弥漫性大 B 细胞淋巴瘤患者自体移植后 MYC/BCL2 表达和细胞起源的临床相关性。
Bone Marrow Transplant. 2023 Sep;58(9):1000-1007. doi: 10.1038/s41409-023-02006-3. Epub 2023 May 18.
4
[Clinical features and prognosis of 166 cases of MYC/BCL2 double-expression diffuse large B-cell lymphoma].166例MYC/BCL2双表达弥漫大B细胞淋巴瘤的临床特征与预后
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):771-777. doi: 10.3760/cma.j.issn.0253-2727.2022.09.010.
5
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool.数字液滴PCR在血液系统恶性肿瘤中的应用：一种新型实用的分子工具。
Diagnostics (Basel). 2022 May 24;12(6):1305. doi: 10.3390/diagnostics12061305.